Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $6.71

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.7143.

A number of equities analysts have weighed in on NMRA shares. Mizuho set a $6.00 price target on Neumora Therapeutics in a research report on Monday, January 5th. Leerink Partners started coverage on Neumora Therapeutics in a research report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Finally, Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $4.00 to $7.00 in a research note on Monday, December 1st.

Neumora Therapeutics Stock Performance

Shares of NMRA opened at $1.93 on Friday. The company has a market cap of $322.48 million, a PE ratio of -1.31 and a beta of 2.46. The firm has a 50-day moving average of $2.73 and a 200-day moving average of $2.32. Neumora Therapeutics has a one year low of $0.61 and a one year high of $3.65. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Monday, March 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, equities analysts forecast that Neumora Therapeutics will post -1.61 earnings per share for the current year.

More Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Company-released data highlighted a promising signal for NMRA-511 (Alzheimer’s agitation), with effect sizes in a pre-specified population comparable to competing pivotal studies — this is the key clinical upside that investors may view as value-creating if replicated. Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Unusually large options buying: traders purchased ~2,812 call contracts (≈+309% vs. normal), signaling speculative bullish positioning or hedging ahead of upcoming trial readouts. This can amplify intraday moves and suggests elevated short-term interest. Charting a Course for Breakthroughs in Brain Diseases
• Neutral Sentiment: Company reported Q4 results and provided a business update; the press release and call offer more color on pipeline priorities and cash runway but did not materially change guidance. Investors will be watching upcoming KOASTAL study readouts and NMRA-511 follow-up. Q4 Press Release
• Neutral Sentiment: Media coverage framed the quarter as a pipeline-forward update despite share weakness; headlines noted the company “topped” forecasts in some outlets while shares slipped — read the details behind the numbers. Neumora tops Q4 earnings forecasts as pipeline advances, shares slip
• Neutral Sentiment: Full earnings call transcript is available for investors who want management’s tone on enrollment progress, cash runway, and development priorities ahead of Q2 data. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Clinical and analyst reaction risk: KOASTAL-1 (navacaprant in MDD) failed its primary endpoint, prompting at least one analyst downgrade (Strong Buy → Hold). KOASTAL-2/3 remain enrolling with topline expected in Q2 2026, but KOASTAL-1’s failure raises uncertainty about the program’s ultimate success and is a key near-term negative driver. Downgrading After Navacaprant Development Setback
• Negative Sentiment: Small Q4 EPS miss: reported EPS was ($0.35) vs. consensus ($0.34), a minor miss but enough to add selling pressure in conjunction with the clinical uncertainty. Earnings coverage / summary

Insider Activity at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 23,387 shares of company stock valued at $82,647 in the last 90 days. 26.80% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legacy Private Trust Co. raised its holdings in Neumora Therapeutics by 35.7% in the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after acquiring an additional 5,000 shares during the period. Vanguard Personalized Indexing Management LLC lifted its position in Neumora Therapeutics by 10.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after acquiring an additional 6,233 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after acquiring an additional 8,383 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Neumora Therapeutics during the fourth quarter worth approximately $27,000. Finally, Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics in the third quarter valued at approximately $31,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.